الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 164 |  |  |
| | | from | 164 | | |
Abstract
The reported Schistosoma mansoni genome provides the researchers with several avenues required for future development of new drugs and feasible vaccine. Progress in schistosome genome research enabled investigators to move rapidly from genome sequences to vaccine development. A putative vaccine would primarily protect against the accumulation of eggs in the body thereby reducing the risk for secondary symptoms following the egg-associated granuloma formation. However, the type and strength of the immune responses required are not known and the experimental animals used for the study of Schistosoma mansoni infection do not lend themselves well to test the long-term impact of different levels of resistance .Vaccination can either be targeted towards: 1) the prevention of infection; 2) the reduction of possibility of transmission and re-infection; 3) reduction in adult worm burden which may be the ”gold standard” for anti-schistosome vaccine development; 4) the reduction of parasite fecundity; or 5) anti-pathology mechanisms and reduction of subsequent complications. Schistosome eggs are responsible for both pathology and transmission hence, a vaccine targeted on parasite fecundity and egg viability also appears to be entirely relevant.